 |
 Video: What is a Stock Split?
|
|
|
| NLS Pharmaceutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system disorders with unmet medical needs. Co.'s main compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary controlled release formulation, is being developed for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). Co.'s focus includes its primary product candidate: Quilience, for the treatment of excessive daytime sleepiness and cataplexy associated with narcolepsy, and Nolazol, for the treatment of ADHD. According to our NLS Pharmaceutics stock split history records, NLS Pharmaceutics has had 0 splits. | |
|
NLS Pharmaceutics (NLSP) has 0 splits in our NLS Pharmaceutics stock split history database.
Looking at the NLS Pharmaceutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NLS Pharmaceutics shares, starting with a $10,000 purchase of NLSP, presented on a split-history-adjusted basis factoring in the complete NLS Pharmaceutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/01/2021 |
|
| End date: |
05/01/2024 |
|
| Start price/share: |
$2.62 |
|
| End price/share: |
$0.13 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-94.89% |
|
| Average Annual Total Return: |
-60.01% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$511.44 |
|
| Years: |
3.24 |
|
|
|
|
|
